NIMS' CPR Motion Platform Device Papers Presented at American Heart Association Meeting.

NORTH BAY VILLAGE, Fla. -- Gary Macleod, Chief Executive Officer, Non-Invasive Monitoring Systems, Inc. (NIMS) (OTCBB:NIMU) announced that Drs. Jose A. Adams, Jorge Bassuk and associates from Mt. Sinai Medical Center of Greater Miami presented three papers dealing with NIMS' patented, prototype CPR motion platform device at the Resuscitation Science Symposium (RESS) of the annual meeting of the American Heart Association (AHA) in Chicago on November 10 to 14. Dr. Adams also served as moderator of a poster symposium at RESS and another of mechanical CPR innovations at AHA.

In a prior publication by Drs. Wu, Adams, Bassuk and associates, stoppage of the heart was induced in two groups of a large animal model for about 18 minutes while either a motion platform with stronger force than the ambulatory human device or a closed chest massage device (Thumper[R]) was employed. Survival rates for the two groups were the same but the motion group had significantly better cardiac function and less signs of inflammation hours after resuscitation than the Thumper group. The two new studies presented at RESS were carried out to help explain the basis for the better results in the motion platform group. These indicated that the cardioprotective and anti-inflammatory effects of the motion platform during CPR were related to this technology producing release of nitric oxide and prostaglandins into the circulation.

Dr. Jose A. Adams, the senior investigator of the group stated that, "Release of nitric oxide and prostacylin into the circulation during heart stoppage may 'condition' the heart and other organs to minimize the known adverse effects of damage caused after circulation is re-established, a phenomenon called ischemia/reperfusion injury." He added that, "Ischemia/reperfusion injury can also occur after treatment of acute blood loss and sepsis, and, following heart attacks and strokes but a great deal more research needs to be done before this indication can be advocated for a clinical trial."

Dr. Marvin Sackner, Chairman of the Board of Directors stated that the device for human, non-CPR use is called the "Exer-Rest," which is a platform that repetitively moves a supine person lying on a mattress in a head to foot direction at about 140 times a minute with a displacement of 3/4 inch or less over a period of 30 to 45 minutes. A clinical trial is planned to support the intended use of "Exer-Rest" for temporary relief of musculoskeletal pain associated with osteoarthritis of the hips in order to meet FDA approval for its marketing in the United States.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.